Nora Volkow from the National Institute on Drug Abuse reiterated the decision of (then) two dozen states to allow medical marijuana to be used in one way or another in their jurisdictions. This should open everyone’s eyes to the sanctioning of a non-addictive, non-psychoactive substance which has been linked to benefits for patients suffering from seizure disorders, quite a few neurodegenerative disorders or pain resulting from cancer.
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.